Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bi-weekly versus tri-weekly cabazitaxel plus prednisone in elderly mCRPC
DRKS00017467Phase 3Completed
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)Georges Pompidou European Hospital 20 rue Leblanc
- Start
- Jun 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)Georges Pompidou European Hospital 20 rue Leblanc. Primary endpoint: Safety of cabazitaxel schedules. Started Jun 2019; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on DRKS00017467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00017467.